Abstract
Background There is limited data on the effectiveness of the SARS-CoV-2 monovalent XBB.1.5 variant vaccine against COVID-19 mortality
Methods We used Australian census data linked to the Australian Immunisation Register and death registrations to estimate COVID-19 booster effectiveness according to booster type and recency in adults aged 65+ years in Australia during August 2023-February 2024, a period dominated firstly by XBB-related SARS-CoV-2 Omicron subvariants and then the BA.2.86-related JN.1. Survival analysis, adjusted for age, sex, and other sociodemographic and health measures, was used to estimate vaccine effectiveness.
Results We followed 4.12 million adults aged 65+ years from 1 August 2023 to 29 February 2024. By 29 February, 581146 doses of the XBB.1.5 vaccine were administered, and 1620 COVID-19-specific deaths occurred. COVID-19 mortality rates were 72/100000 person-years in people who received a COVID-19 booster >365 days earlier, and 21/100000 in those who received the XBB.1.5 booster in the last 3 months. The relative vaccine effectiveness (rVE) of XBB.1.5 booster receipt in the last 3 months against COVID-19 mortality was 74.7% (95%CI 59.9-84.1%). The rVE for those receiving other booster types in the last 3 months was 51.6% (39.3-61.4%). Booster rVE against COVID-19 mortality waned. Compared to those who received a COVID-19 booster >365 days earlier, rVE for a booster within 3-6 months earlier was 31.2% (18.9-41.6%) and for a booster received 6-12 months earlier rVE was 13.1% (1.8-23.2%). rVE estimates were similar in analyses restricted to 1 December 2023 to 29 February 2024 when the dominant Omicron subvariant was JN.1.
Conclusions Recent booster vaccination with the XBB.1.5 monovalent COVID-19 vaccine is highly effective in preventing COVID-19 mortality including in the period when the JN.1 subvariant circulated, supporting recommendations for 6-monthly boosting in older adults. Evaluation of vaccination effectiveness against other health outcomes, such as COVID-19 hospitalisations and ICU admission, would help further document vaccination benefits.
Competing Interest Statement
BL's institution receives grant funding from the Australian National Health and Medical Research Council and the Medical Research Future Fund and Wellcome Trust. From 2019-2023 BL was a member of the Australian Technical Advisory Group on Immunisation. KM's institution has received funding from Australian and State Government Departments of Health, Australian National Health and Medical Research Council, GAVI, WHO and Wellcome Trust. KM has served as an expert witness for State Governments.
Funding Statement
This study was funded the Health Economics and Research Division in the Australian Government Department of Health and Aged Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was conducted as part of monitoring the Australian Governments COVID-19 vaccine program and the Sydney Childrens Hospital Human Research Ethics Committee granted this work exemption from ethical review. All data used were deidentified and all results where counts or rates are provided are perturbed according to the Australian Bureau of Statistics methods to prevent disclosure of small numbers and potential reidentification.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data used for this study are available upon reasonable request to the data custodians of the PLIDA resource.
